Search
Clenoliximab
go.drugbank.com/drugs/DB06241ExperimentalClenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
Guanabenz
go.drugbank.com/drugs/DB00629ApprovedWithdrawnGuanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.
Florbetaben F-18
go.drugbank.com/drugs/DB09148ApprovedInvestigationalFlorbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaqu...
Flucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Cloxacillin
go.drugbank.com/drugs/DB01147ApprovedInvestigationalVet approvedA semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.
Cyanocobalamin Co-60
go.drugbank.com/drugs/DB09387ApprovedWithdrawnCyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.
Digitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnIt has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Pentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Anacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigationalIt is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides … Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.
Bertilimumab
go.drugbank.com/drugs/DB05429InvestigationalBertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.